{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:27:31Z","timestamp":1790195251833,"version":"4.1.0"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>\n                      The study was performed to evaluate\n                      <jats:italic toggle=\"yes\">in silico<\/jats:italic>\n                      binding ability of lutein and rosmarinic acid (RA) with the envelope domain III (EDIII) proteins of the four serotypes of dengue virus (DENV), enlightening potential antiviral activity of the two compounds.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MATERIALS AND METHODS:<\/jats:title>\n                    <jats:p>EDIII protein structures for the four DENV serotypes were retrieved from RCSB Protein data bank (PDB) and used as receptors. Four ligands of lutein and four of RA were selected from the ZINC database and used for computational molecular docking and ligand interaction analysis with the four receptors using bioinformatics tools like AutoDock Vina and Molecular Operating Environment (MOE) software.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>The EDIII of the four serotypes demonstrated significant interaction with ligands of lutein and RA. RA ligand ZINC00899870, particularly presented best binding energy values of -6.4, -7.0, and -6.9 kcal\/mol with EDIII of serotype DENV-1, DENV-2, and DENV-4 respectively. Whereas, lutein ligand, ZINC14879959 presented best binding energy value of -7.9 kcal\/mol for EDIII of serotype DENV-3. From the results predicted by MOE, the hydroxyl (OH) of 3, 4-dihydroxyphenyl group of RA ligand ZINC00899870 is actively involved in interaction with all four serotypes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>\n                      RA is a competent candidate for further evaluation of potential\n                      <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                      antiviral activity that can be effective in conferring protection against the four serotypes of DENV.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijp.ijp_576_19","type":"journal-article","created":{"date-parts":[[2021,12,29]],"date-time":"2021-12-29T23:51:20Z","timestamp":1640821880000},"page":"471-479","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["In silico binding analysis of lutein and rosmarinic acid against envelope domain III protein of dengue virus"],"prefix":"10.4103","volume":"53","author":[{"given":"Ritesh","family":"Panchal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanket","family":"Bapat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeepan","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhay","family":"Chowdhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20240903","first-page":"19839","article-title":"Dengue viruses \u2013 An overview","volume":"3","author":"B\u00e4ck","year":"2013","journal-title":"Infect Ecol Epidemiol"},{"key":"R2-6-20240903","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/QCO.0b013e32835fb938","article-title":"The pathogenesis of dengue","volume":"26","author":"Yacoub","year":"2013","journal-title":"Curr Opin Infect Dis"},{"key":"R3-6-20240903","doi-asserted-by":"crossref","first-page":"11383","DOI":"10.1128\/JVI.01108-14","article-title":"Immunodominance changes as a function of the infecting dengue virus serotype and primary versus secondary infection","volume":"88","author":"Weiskopf","year":"2014","journal-title":"J Virol"},{"key":"R4-6-20240903","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1126\/science.1185181","article-title":"Cross-reacting antibodies enhance DENV infection in humans","volume":"328","author":"Dejnirattisai","year":"2010","journal-title":"Science"},{"key":"R5-6-20240903","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coviro.2019.02.002","article-title":"Structural perspectives of antibody-dependent enhancement of infection of dengue virus","volume":"36","author":"Morrone","year":"2019","journal-title":"Curr Opin Virol"},{"key":"R6-6-20240903","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1016\/j.vaccine.2015.05.010","article-title":"The dengue vaccine pipeline: Implications for the future of dengue control","volume":"33","author":"Schwartz","year":"2015","journal-title":"Vaccine"},{"key":"R7-6-20240903","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1128\/CMR.00102-15","article-title":"Approved antiviral drugs over the past 50 years","volume":"29","author":"De Clercq","year":"2016","journal-title":"Clin Microbiol Rev"},{"key":"R8-6-20240903","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.4065\/mcp.2011.0309","article-title":"Antiviral drugs for viruses other than human immunodeficiency virus","volume":"86","author":"Razonable","year":"2011","journal-title":"Mayo Clin Proc"},{"key":"R9-6-20240903","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.drudis.2019.04.006","article-title":"Expanding the activity spectrum of antiviral agents","volume":"24","author":"Ianevski","year":"2019","journal-title":"Drug Discov Today"},{"key":"R10-6-20240903","doi-asserted-by":"crossref","first-page":"E338","DOI":"10.3390\/v9110338","article-title":"Structures and functions of the envelope glycoprotein in flavivirus infections","volume":"9","author":"Zhang","year":"2017","journal-title":"Viruses"},{"key":"R11-6-20240903","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1093\/infdis\/jiw423","article-title":"Current status of dengue therapeutics research and development","volume":"215","author":"Low","year":"2017","journal-title":"J Infect Dis"},{"key":"R12-6-20240903","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1017\/S1462399408000665","article-title":"Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection","volume":"10","author":"Pierson","year":"2008","journal-title":"Expert Rev Mol Med"},{"key":"R14-6-20240903","doi-asserted-by":"crossref","first-page":"4637861","DOI":"10.1155\/2018\/4637861","article-title":"Non-Provitamin A and Provitamin A carotenoids as immunomodulators: Recommended dietary allowance, therapeutic index, or personalized nutrition?","volume":"2018","author":"Toti","year":"2018","journal-title":"Oxid Med Cell Longev"},{"key":"R15-6-20240903","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1002\/ptr.3155","article-title":"In vitro antiviral activity of lutein against hepatitis B virus","volume":"24","author":"Pang","year":"2010","journal-title":"Phytother Res"},{"key":"R16-6-20240903","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1159\/000335590","article-title":"Melissa officinalis extract inhibits attachment of herpes simplex virus in vitro","volume":"58","author":"Astani","year":"2012","journal-title":"Chemotherapy"},{"key":"R17-6-20240903","doi-asserted-by":"crossref","first-page":"e0197664","DOI":"10.1371\/journal.pone.0197664","article-title":"Rosmarinic acid is a novel inhibitor for Hepatitis B virus replication targeting viral epsilon RNA-polymerase interaction","volume":"13","author":"Tsukamoto","year":"2018","journal-title":"PLoS One"},{"key":"R18-6-20240903","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1128\/AAC.00041-07","article-title":"Antiviral and anti-inflammatory effects of rosmarinic acid in an experimental murine model of Japanese encephalitis","volume":"51","author":"Swarup","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"R19-6-20240903","first-page":"069567","article-title":"Possible antiviral effects of neem (Azadirachta indica) on Dengue virus","volume":"3","author":"Yeturu","year":"2020","journal-title":"bioRxiv"},{"key":"R20-6-20240903","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10867-018-9515-6","article-title":"Dynamics and binding interactions of peptide inhibitors of dengue virus entry","volume":"45","author":"Isa","year":"2019","journal-title":"J Biol Phys"},{"key":"R21-6-20240903","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1002\/prot.21806","article-title":"Solution structure and neutralizing antibody binding studies of domain III of the dengue-2 virus envelope protein","volume":"70","author":"Huang","year":"2008","journal-title":"Proteins"},{"key":"R22-6-20240903","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.bbapap.2012.09.007","article-title":"Stereochemical features of the envelope protein Domain III of dengue virus reveals putative antigenic site in the five-fold symmetry axis","volume":"1834","author":"Soares","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"R23-6-20240903","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.addr.2016.05.007","article-title":"BDDCS, the rule of 5 and drugability","volume":"101","author":"Benet","year":"2016","journal-title":"Adv Drug Deliv Rev"},{"key":"R24-6-20240903","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3389\/fphar.2013.00038","article-title":"Lazar: A modular predictive toxicology framework","volume":"4","author":"Maunz","year":"2013","journal-title":"Front Pharmacol"},{"key":"R25-6-20240903","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1093\/nar\/gkg500","article-title":"Multiple sequence alignment with the clustal series of programs","volume":"31","author":"Chenna","year":"2003","journal-title":"Nucleic Acids Res"},{"key":"R26-6-20240903","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.csbj.2014.09.001","article-title":"3D representations of amino acids-applications to protein sequence comparison and classification","volume":"11","author":"Li","year":"2014","journal-title":"Comput Struct Biotechnol J"},{"key":"R27-6-20240903","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10822-010-9395-8","article-title":"Computer-aided drug design platform using PyMOL","volume":"25","author":"Lill","year":"2011","journal-title":"J Comput Aided Mol Des"},{"key":"R28-6-20240903","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"Software news and update AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J Comput Chem"},{"key":"R29-6-20240903","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.2174\/156802608786786624","article-title":"Medicinal chemistry and the molecular operating environment (MOE): Application of QSAR and molecular docking to drug discovery","volume":"8","author":"Vilar","year":"2008","journal-title":"Curr Top Med Chem"}],"container-title":["Indian Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.IJP_576_19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:51:21Z","timestamp":1787755881000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.IJP_576_19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/ijp.ijp_576_19","relation":{},"ISSN":["0253-7613"],"issn-type":[{"value":"0253-7613","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]}}}